Candel Therapeutics Abstract Accepted for SITC 2026 Poster Presentation
The accepted abstract features aglatimagene besadenovec data in localized prostate cancer.
Related stories
Microsoft Expects to Raise About $25 Billion in U.S. Bond Sale
Microsoft expects to raise about $25 billion through a U.S. bond sale, according to a source.
M impact | EQUITY | Oct 29, 2026, 04:20 PM UTC
NYSE Halt Adds Information on LST at $5.80
L impact | EQUITY | Oct 29, 2026, 04:17 PM UTC
Viridian Metals Plans Private Placement of Up to CA$5 Million
Viridian Metals plans to raise up to CA$5 million through a private placement of units.
L impact | EQUITY | Oct 29, 2026, 04:16 PM UTC
Waterland to Acquire 50% Stake in Milieu Service Groep
Waterland Private Equity agreed to acquire a 50% stake in Milieu Service Groep.
M impact | EQUITY | Oct 29, 2026, 04:14 PM UTC
Shrieve Chemical Acquires Research Solutions Group to Expand Southeast Reach
Shrieve Chemical Company acquired Research Solutions Group to expand its reach in the US Southeast.
M impact | EQUITY | Oct 29, 2026, 04:13 PM UTC
Tide Rock Acquires Electro-Spec
Tide Rock LLC acquired Electro-Spec to establish a surface-finishing platform.
M impact | EQUITY | Oct 29, 2026, 04:13 PM UTC